6 results
Primary: Safety and tolerability.Secondary: Clinical and endoscopic remission, symptomatic clinical remission, clinical response, mucosal healing, health related QoL, CRP, faecal calprotectin, pharmacokinetics.
Primary (Parts 1 and 2)• To evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab Primary (Part 3)Evaluate safety of reduced mandatory monitoring…
The main objective of this study is to investigate gender differences in P-gp function at the blood brain barrier, in order to gain further insight into the impact of these differences on the action of pharmaceuticals (antidepressants and…
Primary Objective:- Number of participants with dose limiting toxicity - Number of participants with treatment-related adverse events - Number of participants with treatment-emergent adverse events- Number of participants with changes in vital signs…
Primary objectiveEvaluation of [18F]MC225 to measure the P-glycoprotein function in Alzheimer*s disease, Mild Cognitive Impairment and Parkinson*s disease. Secondary objectives1. Evaluation of blood-brain barrier integrity using [18F]MC225 and MRI…
Primary:• To Evaluate the safety and tolerability of tarlatamab • Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)Secondary:• Evaluate anti-tumor activity of tarlatamab as assessed by additional measures • Characterize…